Literature DB >> 29956330

Food for thought: formulating away the food effect - a PEARRL review.

Joseph P O'Shea1, René Holm2, Caitriona M O'Driscoll1, Brendan T Griffin1.   

Abstract

OBJECTIVES: Co-ingestion of oral dosage forms with meals can cause substantial changes in bioavailability relative to the fasted state. Food-mediated effects on bioavailability can have significant consequences in drug development, regulatory and clinical settings. To date, the primary focus of research has focused on the ability to mechanistically understand the causes and predict the occurrence of these effects. KEY
FINDINGS: The current review describes the mechanisms underpinning the occurrence of food effects, sheds new insights on the relative frequency for newly licensed medicines and describes the various methods by which they can be overcome. Analysis of oral medicines licensed by either the EMA or FDA since 2010 revealed that over 40% display significant food effects. Due to altered bioavailability, these medicines are often required to be dosed, rather restrictively, in either the fed or the fasted state, which can hinder clinical usefulness.
SUMMARY: There are clinical and commercial advantages to predicting the presence of food effects early in the drug development process, in order to mitigate this risk of variable food effect bioavailability. Formulation approaches aimed at reducing variable food-dependent bioavailability, through the use of bio-enabling formulations, are an essential tool in addressing this challenge and the latest state of the art in this field are summarised here.
© 2018 Royal Pharmaceutical Society.

Keywords:  bio-enabling formulations; food effect; food-drug interactions; formulation screening; gastrointestinal physiology

Mesh:

Substances:

Year:  2018        PMID: 29956330     DOI: 10.1111/jphp.12957

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  10 in total

1.  Understanding Mechanisms of Food Effect and Developing Reliable PBPK Models Using a Middle-out Approach.

Authors:  Xavier J H Pepin; James E Huckle; Ravindra V Alluri; Sumit Basu; Stephanie Dodd; Neil Parrott; Arian Emami Riedmaier
Journal:  AAPS J       Date:  2021-01-04       Impact factor: 4.009

2.  An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor.

Authors:  Yiming Cheng; Liangang Liu; Yongjun Xue; Simon Zhou; Yan Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-06-03       Impact factor: 2.441

3.  Exploring the Relationship of Drug BCS Classification, Food Effect, and Gastric pH-Dependent Drug Interactions.

Authors:  Katie Owens; Sophie Argon; Jingjing Yu; Xinning Yang; Fang Wu; Sue-Chih Lee; Wei-Jhe Sun; Anuradha Ramamoorthy; Lei Zhang; Isabelle Ragueneau-Majlessi
Journal:  AAPS J       Date:  2021-12-27       Impact factor: 4.009

4.  Reduced the Food Effect and Enhanced the Oral Bioavailability of Ivacaftor by Self-Nanoemulsifying Drug Delivery System (SNEDDS) Using a New Oil Phase.

Authors:  Yanfei Miao; Shihua Zhao; Jian Zuo; Jiqin Sun; Jingnan Wang
Journal:  Drug Des Devel Ther       Date:  2022-05-23       Impact factor: 4.319

5.  Supersaturated-Silica Lipid Hybrids Improve in Vitro Solubilization of Abiraterone Acetate.

Authors:  Hayley B Schultz; Paul Joyce; Nicky Thomas; Clive A Prestidge
Journal:  Pharm Res       Date:  2020-03-31       Impact factor: 4.200

Review 6.  Development of In Vitro Dissolution Testing Methods to Simulate Fed Conditions for Immediate Release Solid Oral Dosage Forms.

Authors:  Timothy R Lex; Jason D Rodriguez; Lei Zhang; Wenlei Jiang; Zongming Gao
Journal:  AAPS J       Date:  2022-03-11       Impact factor: 4.009

7.  Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants.

Authors:  Mark Johnson; Teodora Pene Dumitrescu; Samit R Joshi; Ashwin Mathew; Veronica Bainbridge; Joyce Zhan; Max Lataillade
Journal:  Clin Pharmacol Drug Dev       Date:  2022-01-07

8.  New Insights into Using Lipid Based Suspensions for 'Brick Dust' Molecules: Case Study of Nilotinib.

Authors:  Niklas J Koehl; René Holm; Martin Kuentz; Brendan T Griffin
Journal:  Pharm Res       Date:  2019-02-22       Impact factor: 4.200

9.  Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective.

Authors:  Arian Emami Riedmaier; Kevin DeMent; James Huckle; Phil Bransford; Cordula Stillhart; Richard Lloyd; Ravindra Alluri; Sumit Basu; Yuan Chen; Varsha Dhamankar; Stephanie Dodd; Priyanka Kulkarni; Andrés Olivares-Morales; Chi-Chi Peng; Xavier Pepin; Xiaojun Ren; Thuy Tran; Christophe Tistaert; Tycho Heimbach; Filippos Kesisoglou; Christian Wagner; Neil Parrott
Journal:  AAPS J       Date:  2020-09-27       Impact factor: 4.009

10.  Biopharmaceutical Characteristics of Nifurtimox Tablets for Age- and Body Weight-Adjusted Dosing in Patients With Chagas Disease.

Authors:  Heino Stass; Ethel Feleder; Facundo Garcia-Bournissen; Johannes Nagelschmitz; Boris Weimann; Gustavo Yerino; Jaime Altcheh
Journal:  Clin Pharmacol Drug Dev       Date:  2020-10-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.